RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.21
+7.60%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.75x
- Price / sales
- 58.08x
- Price / cash flow
- -12.01x
Enterprise value
- Enterprise value
- $735.6M
- EV / sales
- 36.78x
- EV / EBITDA
- -4.96x
- EV / EBIT
- -4.79x
- Market cap
- $1.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026